To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
Status:
Completed
Trial end date:
2020-02-17
Target enrollment:
Participant gender:
Summary
A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (±
Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.